Kynam Capital Management has disclosed a significant reduction in its stake in Syndax Pharmaceuticals (SNDX), selling 469,041 shares valued at approximately $8.18 million in a recent SEC filing. This move comes as the fund’s position in Syndax now represents 10.81% of its reportable 13F assets under management, reflecting a strategic adjustment while maintaining a substantial holding in the biotech firm.

The sale is noteworthy given Syndax’s impressive stock performance, which has risen over 70% in the past year, significantly outpacing the S&P 500’s 15% gain. The company, focused on developing innovative oncology therapies, reported $172 million in total revenue last year, driven by strong uptake of its products. However, it continues to face challenges with cash burn and operating expenses, typical for clinical-stage biotech firms.

For investors, this transaction highlights a nuanced approach to portfolio management, suggesting Kynam remains confident in Syndax’s long-term potential while recalibrating its exposure in a sector known for volatility and high growth potential.

Source: fool.com